Kiniksa Pharmaceuticals Stock Performance
| KNSA Stock | USD 19.88 0.78 3.78% |
The company secures a Beta (Market Risk) of 0.49, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Kiniksa Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Kiniksa Pharmaceuticals is expected to be smaller as well. At this point, Kiniksa Pharmaceuticals has a negative expected return of -0.1%. Please make sure to verify Kiniksa Pharmaceuticals' potential upside, as well as the relationship between the daily balance of power and price action indicator , to decide if Kiniksa Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Kiniksa Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest conflicting performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return (3.78) | Five Day Return 0.61 | Year To Date Return (0.30) | Ten Year Return 2.11 | All Time Return 2.11 |
Last Split Factor 1:1 | Last Split Date 2024-06-28 |
1 | Acquisition by Megna Michael R of 175 shares of Kiniksa Pharmaceuticals subject to Rule 16b-3 | 11/01/2024 |
2 | Disposition of 89561 shares by Sanj Patel of Kiniksa Pharmaceuticals at 1.59 subject to Rule 16b-3 | 11/06/2024 |
3 | Disposition of 1303 shares by Levy Richard S of Kiniksa Pharmaceuticals subject to Rule 16b-3 | 11/07/2024 |
4 | Disposition of 10000 shares by Eben Tessari of Kiniksa Pharmaceuticals at 1.59 subject to Rule 16b-3 | 11/18/2024 |
5 | Disposition of 8637 shares by Megna Michael R of Kiniksa Pharmaceuticals at 11.1 subject to Rule 16b-3 | 11/27/2024 |
6 | Disposition of tradable shares by Megna Michael R of Kiniksa Pharmaceuticals at 11.1 subject to Rule 16b-3 | 11/29/2024 |
7 | Disposition of 8969 shares by Ragosa Mark of Kiniksa Pharmaceuticals at 21.45 subject to Rule 16b-3 | 12/03/2024 |
8 | Acquisition by Ragosa Mark of 5024 shares of Kiniksa Pharmaceuticals at 10.76 subject to Rule 16b-3 | 12/04/2024 |
9 | Disposition of 8969 shares by Ragosa Mark of Kiniksa Pharmaceuticals at 21.27 subject to Rule 16b-3 | 12/06/2024 |
10 | Disposition of 18860 shares by Ragosa Mark of Kiniksa Pharmaceuticals at 11.1 subject to Rule 16b-3 | 12/09/2024 |
11 | Kiniksa Pharmaceuticals CFO sells shares worth 593,997 | 12/10/2024 |
12 | Disposition of 16017 shares by Eben Tessari of Kiniksa Pharmaceuticals at 1.59 subject to Rule 16b-3 | 12/16/2024 |
13 | Kiniksa Pharmaceuticals to Present at J.P. Morgan Healthcare Conference | 01/06/2025 |
14 | Disposition of 1750 shares by Ragosa Mark of Kiniksa Pharmaceuticals subject to Rule 16b-3 | 01/07/2025 |
15 | Kiniksa Pharmaceuticals Reports Strong Growth in ARCALYST Revenue for 2024 | 01/13/2025 |
16 | Disposition of 12323 shares by Eben Tessari of Kiniksa Pharmaceuticals at 18.13 subject to Rule 16b-3 | 01/15/2025 |
17 | Proactive Strategies - Stock Traders Daily | 01/16/2025 |
18 | Acquisition by Baker Bros. Advisors Lp of 4730 shares of Kiniksa Pharmaceuticals subject to Rule 16b-3 | 01/27/2025 |
| Begin Period Cash Flow | 122.7 M |
Kiniksa |
Kiniksa Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 2,148 in Kiniksa Pharmaceuticals on November 2, 2024 and sell it today you would lose (160.00) from holding Kiniksa Pharmaceuticals or give up 7.45% of portfolio value over 90 days. Kiniksa Pharmaceuticals is currently does not generate positive expected returns and assumes 2.2923% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than Kiniksa, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kiniksa Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kiniksa Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kiniksa Pharmaceuticals, and traders can use it to determine the average amount a Kiniksa Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0457
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KNSA |
Estimated Market Risk
| 2.29 actual daily | 20 80% of assets are more volatile |
Expected Return
| -0.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Kiniksa Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kiniksa Pharmaceuticals by adding Kiniksa Pharmaceuticals to a well-diversified portfolio.
Kiniksa Pharmaceuticals Fundamentals Growth
Kiniksa Stock prices reflect investors' perceptions of the future prospects and financial health of Kiniksa Pharmaceuticals, and Kiniksa Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kiniksa Stock performance.
| Return On Equity | -0.0215 | ||||
| Return On Asset | -0.0316 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 1.22 B | ||||
| Shares Outstanding | 41.57 M | ||||
| Price To Earning | (7.20) X | ||||
| Price To Book | 3.28 X | ||||
| Price To Sales | 3.74 X | ||||
| Revenue | 270.26 M | ||||
| Gross Profit | 234.44 M | ||||
| EBITDA | (22.86 M) | ||||
| Net Income | 14.08 M | ||||
| Cash And Equivalents | 138.21 M | ||||
| Cash Per Share | 1.99 X | ||||
| Total Debt | 12.26 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 4.13 X | ||||
| Book Value Per Share | 6.06 X | ||||
| Cash Flow From Operations | 13.3 M | ||||
| Earnings Per Share | (0.12) X | ||||
| Market Capitalization | 1.44 B | ||||
| Total Asset | 526.32 M | ||||
| Retained Earnings | (477.95 M) | ||||
| Working Capital | 212.63 M | ||||
| Current Asset | 54.44 M | ||||
| Current Liabilities | 10.39 M | ||||
About Kiniksa Pharmaceuticals Performance
By analyzing Kiniksa Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Kiniksa Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Kiniksa Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kiniksa Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 180.87 | 137.66 | |
| Return On Tangible Assets | 0.02 | 0.03 | |
| Return On Capital Employed | (0.05) | (0.05) | |
| Return On Assets | 0.02 | 0.03 | |
| Return On Equity | 0.04 | 0.04 |
Things to note about Kiniksa Pharmaceuticals performance evaluation
Checking the ongoing alerts about Kiniksa Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kiniksa Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kiniksa Pharmaceuticals generated a negative expected return over the last 90 days | |
| Latest headline from MacroaxisInsider: Acquisition by Baker Bros. Advisors Lp of 4730 shares of Kiniksa Pharmaceuticals subject to Rule 16b-3 |
- Analyzing Kiniksa Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kiniksa Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Kiniksa Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kiniksa Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kiniksa Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kiniksa Pharmaceuticals' stock. These opinions can provide insight into Kiniksa Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Kiniksa Stock analysis
When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |